Persistence and determinants of statin therapy among middle‐aged patients for primary and secondary prevention

Abstract

This analysis indicates that barriers to persistence occur early in the therapeutic course. Overall persistence with statins is low, and particularly among patients with few other cardiovascular risk factors.